The present invention provides a novel method for the classification of adjuvants. In one embodiment, the present invention provides a method for generating organ transcriptome profiles for adjuvants, said method comprising: (A) a step for obtaining expression data by performing transcriptome analysis for at least one organ of a target organism by using at least two adjuvants; (B) a step for clustering the adjuvants with respect to the expression data; and (C) a step for generating the organ transcriptome profile for the adjuvants on the basis of the clustering.

An internal prediction method includes acquiring an image of a cell aggregate, calculating a feature amount related to a shape of the cell aggregate on the basis of the image, and outputting structure information related to an internal structure of the cell aggregate on the basis of the feature amount.

The present invention relates to the use of organic and highly water-soluble compatible solutes or a solute mixture, preferably in the form of an inhalable, oropharyngeally, nasally and intravenously administrable composition, in the prevention or treatment of diseases caused by ss(+)RNA viruses of the Coronavriridae family, preferably of those diseases caused by SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-HKU1, HCoV-OC43, HCoV-NL63 and/or HCoV-229E. Particularly suitable solutes in the meaning of the invention are ectoine and its derivatives, Glycoin, mannosylglycerate (Firoin) and mannosylglyceramide (Firoin-A), which, due to their strong water-binding capacity, reduce the binding of the viruses to the receptors of the host cell in the transitional epithelium, e.g. eye, in the internal epithelium, e.g. lung, and in the endothelium and thus reduce or prevent the multiplication of the viruses. According to the invention, prevention is enabled by a reduced infectious sputum and breath, and treatment and rehabilitation of the affected tissues is enabled by the membrane protective properties of the compatible solutes according to the invention.

The invention relates to methods for selective quantification of A-beta or alpha-synuclein aggregates comprising the immobiliZation of anti-A-beta or alpha-synuclein antibodies on a substrate, application of the stool sample to be tested to the substrate, addition of probes labelled for detection which by specific binding to A-beta or alpha-synuclein aggregates mark these and detection of the marked aggregates.

Provided herein is a method of identifying a compound that induces the formation of Hepatitis B Virus (HBV) aberrant viral capsid structures.

Methods of assessing the efficacy of an agent in treating a disease or disorder are provided that include determining whether the agent causes, or inhibits, direct or indirect recruitment and/or ubiquitination and/or degradation of argininosuccinate synthetase 1 (ASS1).

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

The present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets. The present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.

Residual semi-recurrent neural networks (RSNN) can be configured to receive both time invariant input and time variant input data to generate one or more time series predictions. The time invariant input can be processed by a multilayer perceptron of the RSNN. The output of the multilayer perceptron can be used as an initial state for a recurrent neural network unit of the RSNN. The recurrent neural network unit can also receive time invariant input, and process the time invariant input with the time invariant input to generate an output. The outputs of the multilayer perceptron and the recurrent neural network unit can be combined to generate the one or more time series predictions.

Present invention is related to a tumor microenvironment on chip or a biochip for cell therapy having a carrier, a first cell or tissue culture area and a second cell or tissue area imbedded within the carrier. The present invention provides a biochip successfully cooperating micro fluidic technology and cell culture achieving the goal for detecting or testing the function of cell therapy for cancer or tumor.